Evidence map›Paper›PMID 42027441›Full record

ArticleTanaffos2025

Traditional and Short Course Treatment for Multidrug-Resistant Tuberculosis: A Comparative Study in National Referral Centers.

Parvaneh Baghaei, Jonathon R Campbell, Amirmohsen Mahdavian, Zahra Abtahian, Majid Marjani, Afshin Moniri, Mohammad Varahram, Mehdi Kazempour, Payam Tabarsi

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Parvaneh BaghaeiClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jonathon R CampbellDepartment of Epidemiology, Biostatistics, and Occupational Health, Faculty of Medicine, McGill University, Montreal, Canada.
Amirmohsen MahdavianClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra AbtahianClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Majid MarjaniClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Afshin MoniriClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad VarahramMycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdi KazempourDepartment of Biostatistics, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Payam TabarsiClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Treatment of multidrug-resistant tuberculosis (MDR-TB) is difficult, expensive, and requires prolonged periods of time. Recent studies recommended short-course therapy (shorter regimen) for 9 months to one year. This study aimed to evaluate the response of the short-course therapy compared with traditional treatment in MDR-TB patients. Materials and Methods: From all 94 referred MDR-TB cases, 48 patients were included in this study. Shorter regimen consisted of Moxifloxacin, Prothionamide, Amikacin, Clofazimine, Linezolid, Ethambutol, Pyrazinamide, and Cycloserine, and longer regimens consisted of the mentioned drugs, except Clofazimine and Linezolid, were prescribed randomly: in equal (24 in each group). The patients were monitored and evaluated for any complications and were followed for five years for relapse. Results: The median age was 39 years. The median interval for smear conversion was 30 days (20- 58 days) and was shorter in the short-course group (36 vs. 49 days). Also, the mean interval of sputum culture conversion in the shorter group and standard was 32 and 56 days, respectively, which is not related to the outcome of treatment. Eight of twelve patients who developed severe adverse effects were in shorter regimen. There was no difference between the two groups for the outcome of TB treatment. There is no relation between the outcome and other factors. None of them relapsed after three years following the end of the treatment. Conclusion: Shorter treatment can increase the cure rate and cooperation and adherence of the patients. It would be better to consider a shorter regimen in the national TB program for strengthening favorable treatment.

Indexed as

Adverse effectsMultidrug resistantOutcomeShorter treatment

Identifiers

PMID42027441
PMCPMC13102292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.